Harpreet S. Dhaliwal - 17 Apr 2025 Form 3 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
17 Apr 2025
Net transactions value
$0
Form type
3
Filing time
25 Apr 2025, 16:13:50 UTC
Previous filing
04 Jan 2023
Next filing
04 Sep 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 36,083 17 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 96,010 $25.06 Direct F2
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 45,000 $24.79 Direct F3
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 15,000 $47.95 Direct F4
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 62,143 $41.67 Direct F5
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 30,000 $73.82 Direct F6
holding PCVX Performance Stock Option (right to buy) 17 Apr 2025 Common Stock 28,907 $102.70 Direct F7
holding PCVX Performance Restricted Stock Units 17 Apr 2025 Common Stock 11,783 $0.000000 Direct F8
holding PCVX Stock Option (right to buy) 17 Apr 2025 Common Stock 44,903 $74.22 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount includes 23,584 restricted stock units ("RSUs") that, upon vesting, will be settled in shares of the Issuer's Common Stock on a 1-for-1 basis. The RSUs were granted in four tranches: On March 2, 2022; March 1, 2023; February 29, 2024; and February 27, 2025. The RSUs vest(ed) as to 25% of the shares subject to the award at the first sixth-months following grant, and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 1/4 of shares subject to the option vested on October 1, 2022, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F3 1/48 of shares subject to the option vested on April 2, 2022, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F4 1/48 of shares subject to the option vested on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F5 1/48 of shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F6 1/48 of shares subject to the option vested on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F7 As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 28,907 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)).
F8 Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares.
F9 1/48 of shares subject to the option vested on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.